secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001193125-26-107312
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics reports zovegalisib + fulvestrant Phase 1/2 data: 11.1 mo median PFS at RP3D
--------------------------------------------------------------------------------

- Median PFS of 11.1 months (95% CI 7.3-13.0) in 57 evaluable PI3Kα-mutated HR+/HER2- mBC patients.
- Confirmed ORR 43% overall (15/35) and 52% in second-line patients (11/21).
- Safety consistent with prior 600mg fasted; only 4 of 60 patients discontinued due to TRAEs.
- Pharmacokinetics of 400mg BID fed comparable to 600mg BID fasted; most patients above IC80.
- FDA Breakthrough Therapy designation already granted; Phase 3 ReDiscover-2 trial ongoing since mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000119312526107312/0001193125-26-107312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000119312526107312/rlay-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-107312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer